BMI View: Norway’s pharmaceuticals and healthcare markets will continue to expand over the next
decade, with patented medicines to continue to account for the majority of the drug market, reflecting an
ageing population and the adoption of innovative treatments. Meanwhile, as Norway’s economy transitions
away from its dependency on hydrocarbons, this means that public support for investment in innovative
sectors, including the biotech and pharmaceutical sector, will continue to strengthen.
Headline Expenditure Projections
Pharmaceuticals: NOK21.70bn (USD3.48bn) in 2014 to NOK21.97bn (USD2.76bn) in 2015; +1.26% in
local currency terms and -20.7% in US dollar terms. Forecast revised upwards from last quarter.
Healthcare: NOK298.21bn (USD47.86bn) in 2014 to DKK308.64bn (USD38.80bn) in 2014; +3.5% in
local currency terms and -18.9% in US dollar terms. Forecast broadly in line with last quarter.

Table of Contents

BMI Industry View 7
SWOT 9
Political 11
Economic . 12
Operational Risk 13
Industry Forecast 14
Pharmaceutical Market Forecast 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Norway 2011-2019) 16
Healthcare Market Forecast 17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019) 19
Prescription Drug Market Forecast . 20
Pharmaceutical Trade Forecast . 22
Table: Pharmaceutical Trade Data And Forecasts (Norway 2013-2019) 24
Table: Pharmaceutical Trade Data And Forecasts local currency (Norway 2013-2019) 24
Macroeconomic Forecasts 25
Economic Analysis 25
Policy Response Is The Big Question 27
GDP By Expenditure . 30
Table: GDP By Expenditure (Norway 2012-2019) 31
Industry Risk Reward Indices 33
Western Europe Risk/Reward Index . 33
Norway Risk/Reward Index . 38
Rewards . 38
Risks 38
Market Overview 40
Industry Trends And Developments 41
Epidemiology 41
Healthcare Sector . 43
Table: Healthcare Resources (Norway 2009-2014) 45
Table: Healthcare Personnel (Norway 2009-2014) 45
Table: Healthcare Activity (Norway 2009-2014) 46
Clinical Trials . 46
Regulatory Development 47
Pricing Regime 49
Reimbursement Regime . 50
Competitive Landscape . 53
Table: The Top 25 Pharmaceutical Companies In Norway 54
Demographic Forecast 57
Table: Population Headline Indicators (Norway 1990-2025) 58
Table: Key Population Ratios (Norway 1990-2025) 58
Table: Urban/Rural Population & Life Expectancy (Norway 1990-2025) 59
Table: Population By Age Group (Norway 1990-2025) 59
Table: Population By Age Group % (Norway 1990-2025) 60
Glossary 62
Methodology 64
Pharmaceutical Expenditure Forecast Model 64
Healthcare Expenditure Forecast Model 64
Notes On Methodology 65
Risk/Reward Index Methodology 66
Index Overview 67
Table: Pharmaceutical Risk/Reward Index Indicators 67
Indicator Weightings . 68

List of Tables

Table: Pharmaceutical Sales, Historical Data And Forecasts (Norway 2011-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019)
Table: Pharmaceutical Trade Data And Forecasts (Norway 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Norway 2013-2019)
Table: GDP By Expenditure (Norway 2012-2019)
Table: Healthcare Resources (Norway 2009-2014)
Table: Healthcare Personnel (Norway 2009-2014)
Table: Healthcare Activity (Norway 2009-2014)
Table: The Top 25 Pharmaceutical Companies In Norway
Table: Population Headline Indicators (Norway 1990-2025)
Table: Key Population Ratios (Norway 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Norway 1990-2025)
Table: Population By Age Group (Norway 1990-2025)
Table: Population By Age Group % (Norway 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators